What is the 13F Pro Quality Score for BFRI?

13F Pro ranks Biofrontera Inc. (BFRI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BFRI's current score at https://13fpro.ai/research/BFRI (free sign-up required for the full ranking).

Where does 13F Pro source BFRI data?

All Biofrontera Inc. fundamentals and ownership data come directly from SEC EDGAR. Biofrontera Inc. files with the SEC under CIK 1858685. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BFRI in?

Biofrontera Inc. (BFRI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BFRI research updated on 13F Pro?

BFRI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Biofrontera Inc.(BFRI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1858685 BFRI stock profile & AI dashboard →

13F Pro Quality Score

21.3/100

Rank #2,659 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

51.5/100

Profitability

10.1/100

Balance Sheet

1.6/100

Earnings Quality

30.0/100

Free Cash Flow

11.4/100

Institutional Flow

46.7/100

Revenue Scale

8.5/100

Dilution Risk

39.0/100

BFRI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Biofrontera Inc. (BFRI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BFRI at 21.3/100 on a 32-signal composite quality model, placing it at rank #2,659 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.6) and revenue scale (8.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Biofrontera Inc. reports quarterly revenue of $10.1M, net income of $-4.8M, free cash flow of $-75.0K. Top institutional holders of BFRI by reported 13-F value include Rosalind Advisors,, AIGH Capital Management, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. BFRI trades on the Nasdaq exchange and files with the SEC under CIK 1858685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BFRI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biofrontera Inc. directly from SEC EDGAR. Biofrontera Inc.'s 13F Pro composite quality score has ranged between 10 and 32 since 2023, currently 21.3 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.

✦

Fun facts about Biofrontera Inc.

Quirks, history, and lore behind BFRI — the kind of stuff that makes a stock memorable.

1
The Basics
A specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is not a blockbuster drug empire, but a focused dermatology niche player trying to carve out its slice.
3
The History
The company originated in Germany, with its parent founded in the early 2000s, before establishing a U.S. commercial presence and listing on American exchanges.
4
The Secret
Its flagship product uses a photodynamic therapy approach — essentially treating skin lesions by applying a drug and then hitting the area with light. Science or sorcery? Bit of both.
5
The Lore
The company's lead treatment targets actinic keratosis — those rough, precancerous skin patches that dermatologists love to laser off — giving it a very specific but repeat-visit-friendly patient base.
6
The Giveaway
Its flagship drug Ameluz, combined with a BF-RhodoLED lamp, is its photodynamic therapy one-two punch — a German-born dermatology company fighting precancerous skin conditions one light treatment at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$10.1M

Net Income

Q1 2026

$-4.8M

Free Cash Flow

Q1 2026

$-75.0K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+9.5% YoY

$37.3MFY 2024

FY20 $18.8MFY23 $34.1MFY24 $37.3M

Net Income

+11.8% YoY

$-17.8MFY 2024

FY20 $-11.0MFY23 $-20.1MFY24 $-17.8M

Operating Income

+24.1% YoY

$-17.2MFY 2024

FY20 $-9.6MFY23 $-22.7MFY24 $-17.2M

EPS (Diluted)

+75.3% YoY

$-3.22FY 2024

FY20 —FY23 $-13.02FY24 $-3.22

Total Assets

-20.9% YoY

$22.1MFY 2024

FY20 $24.1MFY23 $27.9MFY24 $22.1M

Total Debt

—FY 2024

FY20 —FY23 $3.9MFY24 —

Op. Cash Flow

+58.7% YoY

$-10.3MFY 2024

FY20 $-12.4MFY23 $-24.9MFY24 $-10.3M

Metric	FY 2024	FY 2023	FY 2020
Revenue	$37.3M +9.5%	$34.1M +80.8%	$18.8M
Net Income	$-17.8M +11.8%	$-20.1M -83.2%	$-11.0M
Operating Income	$-17.2M +24.1%	$-22.7M -136.1%	$-9.6M
EPS (Diluted)	$-3.22 +75.3%	$-13.02	—
Total Assets	$22.1M -20.9%	$27.9M +15.7%	$24.1M
Total Debt	—	$3.9M	—
Operating Cash Flow	$-10.3M +58.7%	$-24.9M -101.3%	$-12.4M

Get alerted when BFRI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Biofrontera Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BFRI

Rosalind Advisors, Inc.
$941.6K1,163,962 sh
AIGH Capital Management LLC
$740.4K915,210 sh
GEODE CAPITAL MANAGEMENT, LLC
$88.4K109,300 sh
VANGUARD FIDUCIARY TRUST CO
$49.9K61,697 sh
VANGUARD CAPITAL MANAGEMENT LLC
$42.3K52,254 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$31.2K38,574 sh
XTX Topco Ltd
$18.2K22,493 sh
CITIGROUP INC
$9.6K11,837 sh
Sanctuary Advisors, LLC
$8.3K10,200 sh
BARD ASSOCIATES INC
$5.9K154,900 sh

Fund	Value	Shares
Rosalind Advisors, Inc.	$941.6K	1,163,962
AIGH Capital Management LLC	$740.4K	915,210
GEODE CAPITAL MANAGEMENT, LLC	$88.4K	109,300
VANGUARD FIDUCIARY TRUST CO	$49.9K	61,697
VANGUARD CAPITAL MANAGEMENT LLC	$42.3K	52,254
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$31.2K	38,574
XTX Topco Ltd	$18.2K	22,493
CITIGROUP INC	$9.6K	11,837
Sanctuary Advisors, LLC	$8.3K	10,200
BARD ASSOCIATES INC	$5.9K	154,900

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BFRI on your watchlist

Track score changes the day Biofrontera Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BFRI a good stock to buy?

13F Pro's AI-powered analysis of Biofrontera Inc. (BFRI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BFRI are available on the BFRI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BFRI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BFRI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Biofrontera Inc.'s investment landscape.